Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) EBT (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EBT for 8 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly EBT changed N/A to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$33.3 million for FY2025, 12.95% up from the prior year.
  • EBT for Q4 2025 was -$2.3 million at Actinium Pharmaceuticals, up from -$5.1 million in the prior quarter.
  • The five-year high for EBT was -$2.3 million in Q4 2025, with the low at -$15.9 million in Q1 2025.
  • Average EBT over 5 years is -$9.0 million, with a median of -$8.7 million recorded in 2024.
  • The sharpest move saw EBT crashed 124.32% in 2023, then skyrocketed 55.64% in 2025.
  • Over 5 years, EBT stood at -$8.0 million in 2021, then crashed by 40.3% to -$11.3 million in 2022, then grew by 17.42% to -$9.3 million in 2023, then fell by 24.07% to -$11.6 million in 2024, then soared by 80.15% to -$2.3 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$2.3 million, -$5.1 million, and -$6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.